Sign Up
Stories
Healthcare Innovations: Breakthroughs and Setbacks
Share
Alzheimer's Innovations: A Clinical Adva...
BioArctic's LEQEMBI Wins Awards, Eisai E...
Innovative Therapeutics Insights 2024
89bio to Present pegozafermin for NASH a...
ACTICOR BIOTECH Delays Key Documents
ACTICOR BIOTECH: Financial Report Postpo...
Overview
API
Ventegra launches innovative healthcare program; AstraZeneca gains FDA approval for rare disease drug; Biogen and Eisai delay Alzheimer's therapy application; Eledon pioneers xenotransplants; BMS excels in NSCLC trial with Krazati.
Ask a question
How will the Ventegra Access Program impact the pharmaceutical industry's pricing dynamics?
What challenges might AstraZeneca face in reaching its peak sales target for Voydeya?
What implications do delays in Alzheimer's therapy applications have on patients and research progress?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Jan 2024
Feb 2024
Mar 2024
Apr 2024
Coverage